Adapted from 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest 2004.

(Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Daniel E. Singer, Gregory W. Albers, James E. Dalen, Alan S. Go, Jonathan L. Halperin, and Warren J. Manning
Chest 126: 429S-456S)

Table 2. Target INR for Atrial Fibrillation and Atrial Flutter.

.	INR	DURATION	ALTER NATIVE	ADD
ATRIAL FIBRILLATION	.
A fib, <65 yr, no RF *.	.	Indefinite	ASA 325	.
A fib, <65 yr, with RF *.	2.0-3.0	Indefinite	.	a
A fib, 65-75 yr, no RF *.	2.0-3.0	Indefinite	ASA 325	a
A fib, 65-75 yr, with RF *.	2.0-3.0	Indefinite	.	a
A fib, >75 yr.	2.0-3.0	Indefinite	.	a
A fib, with recurrent emboli.	2.0-3.0	Indefinite	.	Add ASA 80
A fib, with continue emboli.	2.5-3.5	Indefinite	.	Add ASA 80
A fib, following cardiac surgery †	2.5-3.0	††	.	.
A fib, cardiovert <48 hr	Cardiovert w/o anticoag	.	.	.
Pre-cardioversion	2.0-3.0	3 weeks of target INR	TEE pre-cardioversion	.
Post-cardioversion.	2.0-3.0	Indefinite	.	.

ATRIAL FLUTTER.

Same as atrial fibrillation

For Pacific-Asian (exclude caucasian in this region), The INR range of 2.0-3.0 and 2.5-3.5 may be substituted with INR range of 1.6-2.6 and 2.0-3.0 respectively.

• RF* = Risk Factors: History of TIAs, CVA, systemic emboli, hypertension, LV systolic dysfunction, recurrent CHF, DM, rheumatic mitral valve disease, CAD, thyrotoxicosis, left atrial enlargement.
• a = add ASA 80 mg when there are more risk factors or more emboli.
• † = If >48 hours.
• ††  = The anticoagulation treatment should continue for several weeks following reversion to NSR, particularly if patients have risk factors for thromboembolism. There is no need for long term anticoagulation if atrial fibrillation occurs only post operatively and revert or convert to NSR.